Tatricia James

Tatricia James serves as a procurement professional within the Office of the Assistant Secretary for Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services, where she supports the acquisition of critical medical countermeasures to address public health emergencies, including pandemics and bioterrorism threats. Her work centers on securing advanced therapeutics, vaccines, and diagnostic technologies through competitive contracting mechanisms aligned with federal biodefense priorities. She manages complex acquisitions requiring rapid deployment, regulatory compliance, and supply chain resilience, often coordinating with scientific and operational teams to ensure timely delivery of life-saving capabilities. James maintains strategic relationships with specialized biopharmaceutical and advanced delivery technology firms, including Cidara Therapeutics, Aquestive Therapeutics, Rafa Laboratories, and Osivax. These partnerships reflect a focus on innovative medical countermeasures such as antiviral therapeutics, novel drug delivery platforms, and next-generation vaccine candidates. Her contracting approach emphasizes technical rigor, performance-based outcomes, and alignment with BARDA’s mission to accelerate the transition of promising biomedical innovations from development to operational readiness. James’s procurement activity shows no reliance on socioeconomic set-asides, with 100% of awards issued under full and open competition. This reflects a mission-driven prioritization of technical capability and speed over socioeconomic criteria, consistent with the urgency of national preparedness objectives. While small business participation is not formally structured through set-asides, vendors of all sizes compete on technical merit and readiness to meet urgent public health timelines. Her primary procurement activity is classified under NAICS 721110—Hotels (except Casino Hotels) and Motels—which appears to be a misclassification or data anomaly. Given the agency’s mission, this likely reflects an administrative or system-level error; her actual technical domain centers on biomedical countermeasure acquisition, including pharmaceuticals, medical devices, and biologics, requiring deep expertise in FDA-regulated product development and emergency procurement authorities.